AstraZeneca experienced some setbacks last year on its quest to expand its asthma drug Fasenra to treat other conditions like rhinosinusitis and eosinophilic esophagitis. However, the British pharma ...

Dr. Michael Wechsler, Professor of Medicine and Director of The Asthma Institute at National Jewish Health, and International Coordinating Investigator of the MANDARA trial said: “This approval is ...

(RTTNews) - AstraZeneca Plc (AZN.L, AZN) said that results from the MANDARA Phase III trial showed the company's FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated ...

The FDA approved on Wednesday AstraZeneca Plc’s (NASDAQ:AZN) Fasenra (benralizumab) for eosinophilic granulomatosis with polyangiitis (EGPA), a rare, immune-mediated vasculitis (inflammation of the ...

Please provide your email address to receive an email when new articles are posted on . The approval follows positive results from the TATE trial. A new 10 mg dose will be available to accommodate ...

During weeks 48 through 52, a 100% reduction in the OCS dose was observed in 41% of benralizumab-treated patients vs 26% of mepolizumab-treated patients. The Food and Drug Administration (FDA) has ...

Teaming with the Professional Pickleball Association (PPA) in a multiyear deal, AstraZeneca’s seven-year-old Fasenra asthma medication has launched its first-ever sports partnership. The brand began ...

FASENRA also demonstrated a greater improvement in fatigue symptom relief in a single monthly dose compared to placebo Princess U. Ogbogu, Division Chief of Pediatric Allergy, Immunology, and ...

AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab), for use in children. The regulatory body has now approved Fasenra as an add-on maintenance ...

SaveHealth reports seven asthma medication categories, including inhaled corticosteroids and biologics, helping manage ...